This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
A fusee is a practical necessity in watches using a verge escapement, and can also provide considerable benefit with a lever escapement and other high precision types of escapements (Hamiltons WWII era Model 21 chronometer used a fusee in combination with a detent escapement). Keywind watches are also commonly seen with conventional going barrels and other types of mainspring barrels, particularly in American watchmaking.
Degradation of Oligopeptide Sequences in N-(2-Hydroxypropyl)methacrylamide Copolymers by Bovine Spleen Cathepsin B". Die Makromolekulare Chemie 184, 2009–2020 (1983) K. Ulbrich, J. Strohalm, J. Kopeček, "Polymers Containing Enzymatically Degradable Bonds. 6. Hydrophilic Gels Cleavable by Chymotrypsin". Biomaterials 3, 150–154 (1982) J. Kopeček, P. Rejmanová, V. Chytrý, "Polymers Containing Enzymatically Degradable Bonds. 1. Chymotrypsin Catalyzed Hydrolysis of p-Nitroanilides of Phenylalanine and Tyrosine Attached to Side-Chains of Copolymers of N-(2-Hydroxypropyl)methacrylamide". Die Makromolekulare Chemie 182, 799–809 (1981) J. Kopeček, "Soluble Biomedical Polymers". Polymers in Medicine (Wroclaw) 7, 191–221 (1977) Z. Voldřich, Z. Tománek, J. Vacík, J. Kopeček, "Long-Term Experience with the Poly(Glycol Monomethacrylate) Gel in Plastic Operations of the Nose". Journal of Biomedical Materials Research 9, 675–685 (1975) J. Kopeček, H. Bažilová, Poly[N-(2-Hydroxypropyl)methacrylamide]. 1. "Radical Polymerization and Copolymerization". European Polymer Journal J. 9, 7–14 (1973) J. Kopeček, J. Vacík, D. Lím, "Permeability of Membranes Containing Ionogenic Groups". Journal of Polymer Science A-1, 9, 2801–2815 (1971) L. Šprincl, J. Kopeček, D. Lím, "Effect of Porosity of Heterogeneous Poly(Glycol Monomethacrylate) Gels on the Healing-in of Test Implants". Journal of Biomedical Materials Research 5, 447–458 (1971) J. Kopeček, J. Jokl, D. Lím, "Mechanism of Three-Dimensional Polymerization of Glycol Methacrylates" (in German). Journal of Polymer Science C 16, 3877–3889 (1968)
Since radon is a colorless, odorless gas, the only way to know how much is present in the air or water is to perform tests. In the US, radon test kits are available to the public at retail stores, such as hardware stores, for home use, and testing is available through licensed professionals, who are often home inspectors. Efforts to reduce indoor radon levels are called radon mitigation. In the US, the EPA recommends all houses be tested for radon. In the UK, under the Housing Health & Safety Rating System, property owners have an obligation to evaluate potential risks and hazards to health and safety in a residential property. Alpha-radiation monitoring over the long term is a method of testing for radon that is more common in countries outside the United States.
=== Batch reactor === Batch reactors are reactors in which the reactants are put in the reactor at time 0 and react until the reaction is stopped. Consequently, the space time is the same as the average residence time in a batch reactor.
Sources: en.wikipedia.org
Because of an abnormal peripheral blood profile, the response to inflammatory skin conditions in patients with myelomonocytic leukemia can have the appearance of atypical cells at sites of inflammation, confusing the Mohs surgeon. Perineural spread, and benign changes simulating perineural spread. Tumor spreading along a nerve can be difficult to visualize, and sometime benign plasma cells can surround the nerve, simulating cancer. Anatomical area that is difficult to cut and process. Examples would be the ear, and other three-dimensional structures like eyelids. The ability to make a scallop-shaped incision is increasingly difficult when the surgical surface is no longer a flat plane, but is a three-dimensional, rigid structure. Recurrent skin cancer with multiple islands of recurrence. This can occur with either previous excision or after electrodesiccation and curettage. As these residual skin cancers are often bound in scar tissue and present in multiple locations in the scar of the previous surgical defect, they are no longer contiguous in nature. Some surgeons advocate the removal of the complete scar in the treatment of "recurrent" skin cancers. Others advocate removing only the island of local recurrence and leaving the previous surgical scar behind. The decision is often made depending on the location of the tumor and the goal of the patient and physician. Unreported or underreported recurrence. Many patients do not return to the original surgeon to report a recurrence.
Dehydrogenase enzymes transfer electrons from the substrate to an electron carrier; what carrier is used depends on the reaction taking place. Common electron acceptors used by this subclass are NAD+, FAD, and NADP+. Electron carriers are reduced in this process and considered oxidizers of the substrate. Electron carriers are coenzymes that are often referred to as "redox cofactors."
=== Peptide tags === Short tags on proteins are more commonly called "epitope tags." The tags on this list would fall under that category. "Epitope tagging" is the process of adding a short peptide to a protein such that it can be detected using an antibody specific to that peptide (epitope).
Restricting population size is a proposed solution to malnutrition. Thomas Malthus argues that population growth can be controlled by natural disasters and by voluntary limits through "moral restraint." Robert Chapman suggests that government policies are a necessary ingredient for curtailing global population growth. The United Nations recognizes that poverty and malnutrition (as well as the environment) are interdependent and complementary with population growth. According to the World Health Organization, "Family planning is key to slowing unsustainable population growth and the resulting negative impacts on the economy, environment, and national and regional development efforts". However, more than 200 million women worldwide lack adequate access to family planning services. There are different theories about what causes famine. Some theorists, like the Indian economist Amartya Sen, believe that the world has more than enough resources to sustain its population. In this view, malnutrition is caused by unequal distribution of resources and under- or unused arable land. For example, Sen argues that "no matter how a famine is caused, methods of breaking it call for a large supply of food in the Public Distribution System. This applies not only to organizing rationing and control, but also to undertaking work programmes and other methods of increasing purchasing power for those hit by shifts in exchange entitlements in a general inflationary situation."
== Thiers wall (1844) – Territorial reform (1860) == On the proposal of the politician Adolphe Thiers, after whom it would be named, a fortification was built around Paris from 1841 to 1844 by order of Louis-Philippe I. The king was convinced that defending the territory required preventing the capital from falling into the hands of foreign armies, as had occurred in 1814 during the Battle of Paris. Louis-Philippe thus wanted to encircle the city with fortifications to make it impregnable. With fifty-two gates or posterns, this fortification encompassed the capital and all or part of the surrounding communes. In these areas, residents avoided the octroi taxes imposed on Parisians, which the Wall of the Farmers-General enforced as both an administrative boundary and a fiscal burden.By the decree of February 16, 1859, and the law of June 16, 1859, Napoleon III extended Paris’s territory to the Thiers wall. On January 1, 1860, the city expanded from twelve to twenty districts. It absorbed, fully or partially, some nearby suburban communes. The 11 fully annexed communes, moving from southwest to southeast through the north and east, were: Vaugirard, Grenelle, Auteuil, Passy, Batignolles-Monceau, Montmartre, La Chapelle, La Villette, Belleville, Charonne, and Bercy. The 13 partially annexed communes, following the same directional pattern, were: Issy-les-Moulineaux, Neuilly, Clichy, Saint-Ouen, Aubervilliers, Pantin, Le Pré-Saint-Gervais, Bagnolet, Saint-Mandé, Ivry, Gentilly, Vanves, and Montrouge.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.